vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
vTv Therapeutics (Nasdaq: VTVT) has secured an $80 million private placement financing from leading healthcare institutional investors and the T1D Fund. The funding will support the ongoing CATT1 Phase 3 trial of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment.
The PIPE financing includes the sale of 682,018 shares of Class A Common Stock and pre-funded warrants for 4,561,714 shares, with accompanying warrants to purchase 5,243,732 shares. The unit price is set at $15.265 for common stock and $15.255 for pre-funded warrants, with accompanying warrants having an exercise price of $22.71 per share.
The company expects topline data from the CATT1 Phase 3 trial in the second half of 2026. The trial aims to evaluate cadisegliatin's potential in reducing hypoglycemic events and improving glycemic control in T1D patients.
vTv Therapeutics (Nasdaq: VTVT) ha ottenuto un finanziamento in private placement da 80 milioni di dollari da parte di importanti investitori istituzionali nel settore sanitario e del T1D Fund. I fondi sosterranno l’attuale studio CATT1 di fase 3 su cadisegliatin, una possibile prima terapia orale di classe adjunct all’insulina per il trattamento del diabete di tipo 1.
Il finanziamento PIPE prevede la vendita di 682.018 azioni di Classe A Common Stock e warrant pre-finanziati per 4.561.714 azioni, con warrant associati per l’acquisto di 5.243.732 azioni. Il prezzo unitario è fissato a 15,265 $ per le azioni comuni e 15,255 $ per i warrant pre-finanziati, mentre il prezzo di esercizio dei warrant associati è di 22,71 $ per azione.
La società prevede i dati topline dello studio CATT1 di fase 3 nella seconda metà del 2026. Lo studio mira a valutare il potenziale di cadisegliatin nella riduzione degli episodi di ipoglicemia e nel miglioramento del controllo glicemico nei pazienti con T1D.
vTv Therapeutics (Nasdaq: VTVT) ha asegurado una financiación en private placement de 80 millones de dólares por parte de destacados inversores institucionales del sector sanitario y del T1D Fund. La financiación apoyará el actual ensayo CATT1 de fase 3 de cadisegliatin, una posible primera terapia oral adyuvante a la insulina para el tratamiento de la diabetes tipo 1.
La financiación PIPE incluye la venta de 682.018 acciones de Clase A Common Stock y warrants prefinanciados por 4.561.714 acciones, con warrants correspondientes para la compra de 5.243.732 acciones. El precio unitario se fija en 15,265 $ para las acciones ordinarias y 15,255 $ para los warrants prefinanciados, y los warrants asociados tienen un precio de ejercicio de 22,71 $ por acción.
La compañía espera datos topline del ensayo CATT1 de fase 3 en la segunda mitad de 2026. El estudio pretende evaluar el potencial de cadisegliatin para reducir los episodios de hipoglucemia y mejorar el control glucémico en pacientes con DT1.
vTv Therapeutics (Nasdaq: VTVT)가 주요 의료 기관 투자자들과 T1D Fund로부터 8,000만 달러 규모의 사모 투자를 확보했습니다. 이 자금은 제1형 당뇨병 치료를 위한 인슐린 보조제로서의 최초 경구 병용요법 후보인 카디세글리틴의 진행 중인 CATT1 3상 시험을 지원할 예정입니다.
이번 PIPE 자금 조달은 682,018주의 클래스 A 보통주 및 4,561,714주에 대한 프리펀디드 워런트의 판매를 포함하며, 이에 따라 5,243,732주를 매수할 수 있는 워런트가 수반됩니다. 단가 는 보통주에 대해 $15.265, 프리펀디드 워런트에 대해 $15.255로 책정되었으며, 수반 워런트의 행사가격은 주당 $22.71입니다.
회사는 CATT1 3상 시험의 톱라인 데이터를 2026년 하반기에 기대하고 있습니다. 이 시험은 T1D 환자에서 카디세글리틴이 저혈당 발생을 줄이고 혈당 조절을 개선할 수 있는지를 평가하는 것을 목표로 합니다.
vTv Therapeutics (Nasdaq: VTVT) a obtenu un financement en placement privé de 80 millions de dollars de la part d'investisseurs institutionnels majeurs du secteur de la santé et du T1D Fund. Ces fonds soutiendront l'essai CATT1 de phase 3 en cours sur la cadisegliatine, un potentiel premier traitement oral adjuvant à l'insuline pour le diabète de type 1.
Le financement PIPE inclut la vente de 682 018 actions de Class A Common Stock et de bons de souscription préfinancés pour 4 561 714 actions, avec des bons correspondants permettant d'acheter 5 243 732 actions. Le prix unitaire est fixé à 15,265 $ pour les actions ordinaires et 15,255 $ pour les bons préfinancés, les bons associés ayant un prix d'exercice de 22,71 $ par action.
La société attend des données topline de l'essai CATT1 de phase 3 dans la deuxième moitié de 2026. L'étude vise à évaluer le potentiel de la cadisegliatine pour réduire les épisodes d'hypoglycémie et améliorer le contrôle glycémique chez les patients atteints de DT1.
vTv Therapeutics (Nasdaq: VTVT) hat eine 80-Millionen-Dollar-Privatplatzierung von führenden institutionellen Gesundheitsinvestoren und dem T1D Fund erhalten. Die Mittel sollen die laufende CATT1 Phase-3-Studie zu Cadisegliatin unterstützen, einem potenziellen, ersten oralen Zusatztherapeutikum zur Insulinbehandlung bei Typ-1-Diabetes.
Die PIPE-Finanzierung umfasst den Verkauf von 682.018 Aktien der Klasse A Common Stock sowie vorfinanzierten Warrants für 4.561.714 Aktien und begleitenden Warrants zum Kauf von 5.243.732 Aktien. Der Stückpreis beträgt 15,265 $ für Stammaktien und 15,255 $ für vorfinanzierte Warrants; der Ausübungspreis der begleitenden Warrants liegt bei 22,71 $ pro Aktie.
Das Unternehmen erwartet Topline-Daten der CATT1 Phase-3-Studie in der zweiten Hälfte 2026. Die Studie zielt darauf ab, das Potenzial von Cadisegliatin zur Reduktion von Hypoglykämie-Ereignissen und zur Verbesserung der glykämischen Kontrolle bei T1D-Patienten zu bewerten.
- Secured substantial $80 million private placement financing from reputable healthcare investors
- Support from both existing and new institutional investors demonstrates confidence in the company
- Funding provides runway beyond Phase 3 trial topline data expected in H2 2026
- Development of potentially first-in-class oral adjunctive therapy for type 1 diabetes
- Significant dilution through issuance of new shares and warrants
- Securities are not registered under Securities Act of 1933
- Phase 3 trial results not expected until second half of 2026
- Additional regulatory approvals and registrations required for securities
Insights
vTv's $80M financing provides crucial runway for Phase 3 diabetes drug development through topline data readout in 2026.
vTv Therapeutics has secured a substantial
The investment consortium brings impressive validation, combining both existing investors (including the T1D Fund and Samsara BioCapital) with new specialized life sciences investors (Trails Edge Capital Partners and Invus). The T1D Fund's continued support is particularly notable as they exclusively focus on type 1 diabetes breakthroughs.
The structure of this deal includes both direct stock purchases and warrant components. Investors are purchasing 682,018 shares of Class A common stock and pre-funded warrants for 4,561,714 additional shares, with accompanying warrants for 5,243,732 shares at an exercise price of
Cadisegliatin represents a potential breakthrough as an oral adjunctive therapy to insulin for type 1 diabetes management. The CATT1 Phase 3 trial specifically targets reducing hypoglycemic events (dangerous low blood sugar episodes) while improving overall glycemic control - addressing critical unmet needs in diabetes care where insulin therapy alone often proves challenging.
This financing provides vTv with essential capital to complete their pivotal trial and maintain operations beyond the crucial data readout, positioning them well for potential regulatory submissions should results prove positive.
Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes
Topline data from CATT1 Phase 3 trial on track for second half 2026
HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today announced that it has entered into a purchase agreement for an
Investors in the financing include existing investors in the Company: a life sciences-focused institutional investor, Samsara BioCapital, L.P. (“Samsara”), and the T1D Fund. New investors include Trails Edge Capital Partners, and Invus.
TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.
Pursuant to the terms of the purchase agreement, the Company is selling to the investors units consisting of an aggregate of 682,018 shares of the Company’s Class A Common Stock and pre-funded warrants to purchase 4,561,714 shares of the Company’s Class A Common Stock, with accompanying warrants to purchase an aggregate of 5,243,732 shares of the Company’s Class A Common Stock. The purchase price for a unit consisting of one share of Class A Common Stock and an accompanying warrant is
“This financing enables us to continue advancing the development of cadisegliatin, including the CATT1 trial, which is evaluating the potential of cadisegliatin to help reduce the frequency of level 2 and 3 hypoglycemic events and to improve glycemic control in people living with T1D. It will also provide additional runway for the Company following topline data from the study, which is expected in the second half of 2026,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics.
"We are pleased to support vTv as they advance cadisegliatin through the CATT1 Phase 3 trial for people with type 1 diabetes. This funding will enable further investigation of cadisegliatin as an adjunctive therapy to insulin, with the potential to address persistent challenges in glycemic management. The T1D Fund exists to accelerate the development of T1D treatments, prevention, and cures, and this milestone represents meaningful progress on that path," said Elizabeth Mily, CEO of the T1D Fund.
The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. vTv has agreed to file a registration statement with the Securities and Exchange Commission (SEC) pursuant to a registration rights agreement entered into concurrently with the purchase agreement, registering the resale of the shares of common stock and shares of common stock issuable upon the exercise of the pre-funded warrants and other warrants issued in this PIPE.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the satisfaction of the closing conditions set forth in the securities purchase agreement, the expected use of proceeds from the offering, the timing of our clinical trials, the anticipated effect of Phase 3 topline date on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
What is the size and purpose of vTv Therapeutics' (VTVT) private placement financing?
Who are the investors in VTVT's private placement?
What are the terms of VTVT's private placement offering?
When will VTVT's CATT1 Phase 3 trial results be available?
What is cadisegliatin and how could it benefit type 1 diabetes patients?
